MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
PharmaDrug is restructuring approximately $1 million in debt in the form of convertible debentures.
Atai Life Sciences is bolstering its R&D platform with the acquisition of New York-based Kures.
Oregon could become the first U.S. state to LEGALIZE the (medicinal) use of a psychedelic drug.
Psychedelic drug R&D is ramping up rapidly. The number of past and current clinical studies on these substances will surprise you.
Osoyoos Cannabis provides additional details on its previously announced acquisition.
Understanding the drug approval process that leads to drug patents and drug licensing is of critical importance for successful investing in psychedelics.
Mydecine Innovations Group has added one of the world's pre-eminent biotech scientists to its Scientific Advisory Board.
Cybin Corp is partnering with IntelGenx Corp to produce a new delivery system for pharmaceutical-grade psilocybin.
Mydecine's new Scientific Advisor holds over 150 U.S. and international patents and will oversee Mydecine's mycology lab.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now